Nitza Thomasson-Perret

Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France.

Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets.

Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France.

Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France.

NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G?raldine Le Duc, Olivier Tillement and Fran?ois Lux in on December 11, 2015 and is headquartered in Meylan, France.

BrainTale SAS engages in the development and distribution of diagnosis and prognosis tools for brain injured patients. Its products include BrainQuant and BrainScore-coma. The company was founded by Vincent Perlbarg, Julie Rachline, Didier Cassereau, Louis Puybasset, Damien Galanaud, and Lionel Velly on July 6, 2018 and is headquartered in Paris, France.